WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Wedbush PacGrow 2021 Virtual Healthcare Conference


Format: Panel presentation (Infectious Personality) and one-on-one investor meetings

Presentation Date & Time: Wednesday, August 11, 2021, at 4:40 p.m. ET

The webcast of the Wedbush presentation will be accessible in the

News & Events

section of the Entasis website at

https://www.entasistx.com/

.

About Entasis


Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting

Acinetobacter baumannii

infections), zoliflodacin (targeting

Neisseria gonorrhoeae

infections), ETX0282CPDP (targeting

Enterobacteriaceae

infections) and ETX0462 (targeting

Pseudomonas

infections). For more information, visit

www.entasistx.com

.

Company Contact:


Kyle Dow

Entasis Therapeutics

(781) 810-0114


[email protected]

Investor Relations Contact:


Bruce Mackle

LifeSci Advisors

(929) 469-3859


[email protected]